Pharmaron Beijing (03759) plans to offer a discount of approximately 8.50% for a total of 58.44 million shares, raising a net amount of approximately 1.319 billion Hong Kong dollars.

Pharmaron Beijing (03759) announced that on January 14, 2026, the company entered into a placement agreement with placement agents. Each placement agent agreed individually (not jointly, severally or jointly and severally) to act as an agent for the company and to use their best efforts to encourage subscribers to subscribe for a total of 58.44 million new H shares at the placement price per share. The number of placement shares represents approximately 16.57% of the total number of issued H shares after the completion of the placement, and approximately 3.19% of the total number of issued shares. The placement price per share is HK$22.82, representing a discount of approximately 8.50% from the closing market price of H shares on the Hong Kong Stock Exchange on January 14, 2026, which was HK$24.94 per share. Assuming all placement shares are fully subscribed, the expected total amount raised from the placement is approximately HK$1.334 billion. The expected net amount raised from the placement is approximately HK$1.319 billion (with a net price per share of approximately HK$22.56), which will be used as follows: approximately 70% will be used for the company's project development to strengthen the company's laboratory service facilities, drug process development, and production capacity; approximately 10% will be used to repay bank loans and other borrowings to optimize the company's capital structure; and approximately 20% will be used for working capital and other general corporate purposes.